Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
21 authors.
Hugues Allard-ChamardRagon Institute of Mass General, Massachusetts Institute of Technology, and Harvard, Cambridge, MA.ORCID 0000-0001-7850-2658
Kirsty HillierRagon Institute of Mass General, Massachusetts Institute of Technology, and Harvard, Cambridge, MA.ORCID 0000-0001-7080-2293
Michelle L RamseierRagon Institute of Mass General, Massachusetts Institute of Technology, and Harvard, Cambridge, MA.ORCID 0000-0002-9201-7656
Alice BertocchiRagon Institute of Mass General, Massachusetts Institute of Technology, and Harvard, Cambridge, MA.
Naoki KanekoRagon Institute of Mass General, Massachusetts Institute of Technology, and Harvard, Cambridge, MA.ORCID 0000-0002-1349-2660
Katherine PremoRagon Institute of Mass General, Massachusetts Institute of Technology, and Harvard, Cambridge, MA.
Grace YuenRagon Institute of Mass General, Massachusetts Institute of Technology, and Harvard, Cambridge, MA.ORCID 0000-0002-3253-9575
Marshall KarpelRagon Institute of Mass General, Massachusetts Institute of Technology, and Harvard, Cambridge, MA.
Vinay S MahajanRagon Institute of Mass General, Massachusetts Institute of Technology, and Harvard, Cambridge, MA.
Christina TsekeriRagon Institute of Mass General, Massachusetts Institute of Technology, and Harvard, Cambridge, MA.ORCID 0009-0008-3698-1732
Joseph S HongDivision of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA.
Jean VencicDivision of Rheumatology, Faculté de médecine et des sciences de la santé de l'Université de Sherbrooke et Centre de Recherche Clinique Étienne-Le Bel, Sherbrooke, QC, Canada.ORCID 0000-0003-3525-1806
Rory CrottyDepartment of Pathology, Brigham and Women's Hospital, Boston, MA.
Anish V ShardaDivision of Translational Hematology, Yale University School of Medicine, New Haven, CT.ORCID 0000-0003-3856-4277
Sara BarmettlerDivision of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA.
Emma Westermann-ClarkDivision of Allergy and Immunology, Johns Hopkins All Children's Hospital, St. Petersburg, FL.ORCID 0000-0001-5562-234X
Jolan E WalterDivision of Allergy and Immunology, Johns Hopkins All Children's Hospital, St. Petersburg, FL.ORCID 0000-0002-6192-0703
Musie GhebremichaelRagon Institute of Mass General, Massachusetts Institute of Technology, and Harvard, Cambridge, MA.ORCID 0000-0002-8572-1944
Alex K ShalekRagon Institute of Mass General, Massachusetts Institute of Technology, and Harvard, Cambridge, MA.ORCID 0000-0001-5670-8778
Jocelyn R FarmerRagon Institute of Mass General, Massachusetts Institute of Technology, and Harvard, Cambridge, MA.ORCID 0000-0003-4901-9848
Shiv PillaiRagon Institute of Mass General, Massachusetts Institute of Technology, and Harvard, Cambridge, MA.
Funding
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
PATHOPHYSIOLOGY OF HUMAN BLOOD CELLST32HL007574 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI Daniel Evan Bauer · 1985 to 2026
$18.4M
Research Training in Pulmonary Immunology and Allergy at MGHT32HL116275 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI David C Christiani, ANDREW D LUSTER · 2013 to 2026
$8.6M
The importance of the IgG4 glycome in IgG4-related disease(s)U19AI110495 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Ramnik J Xavier · 2014 to 2026
$7.9M
Modeling Risk for Hypogammaglobulinemia, Infections, and Mortality with Chimeric Antigen Receptor (CAR) T-cell TherapyK23AI163350 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BARMETTLER, SARA · 2021 to 2025
$1.1M
Pathogenesis of IgG4 related diseaseK08AI113163 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI MAHAJAN, VINAY SUBHASH · 2014 to 2018
abstractPatients with cytotoxic T-lymphocyte-associated protein 4 (CTLA4) deficiency exhibit profound humoral immune dysfunction, yet the basis for the B-cell defect is not known. We observed a marked reduction in transitional-to-follicular (FO) B-cell development in patients with CTLA4 deficiency, correlating with decreased CTLA4 function in regulatory T cells, increased CD40L levels in effector CD4+ T cells, and increased mammalian target of rapamycin complex 1 (mTORC1) signaling in transitional B cells (TrBs). Treatment of TrBs with CD40L was sufficient to induce mTORC1 signaling and inhibit FO B-cell maturation in vitro. Frequent cell-to-cell contacts between CD40L+ T cells and immunoglobulin D-positive CD27- B cells were observed in patient lymph nodes. FO B-cell maturation in patients with CTLA4 deficiency was partially rescued after CTLA4 replacement therapy in vivo. We conclude that functional regulatory T cells and the containment of excessive T-cell activation may be required for human TrBs to mature and attain metabolic quiescence at the FO B-cell stage.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Congenital T-cell activation impairs transitional-to-follicular B-cell maturation in humans. · full record | OpenQuestion